T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
12 2020
Historique:
received: 25 09 2020
accepted: 18 11 2020
revised: 25 01 2021
pubmed: 29 12 2020
medline: 26 3 2021
entrez: 28 12 2020
Statut: epublish

Résumé

HIV-1 strains harboring immune escape mutations can persist in circulation, but the impact of selection by multiple HLA alleles on population HIV-1 dynamics remains unclear. In Japan, HIV-1 Reverse Transcriptase codon 135 (RT135) is under strong immune pressure by HLA-B*51:01-restricted and HLA-B*52:01-restricted T cells that target a key epitope in this region (TI8; spanning RT codons 128-135). Major population-level shifts have occurred at HIV-1 RT135 during the Japanese epidemic, which first affected hemophiliacs (via imported contaminated blood products) and subsequently non-hemophiliacs (via domestic transmission). Specifically, threonine accumulated at RT135 (RT135T) in hemophiliac and non-hemophiliac HLA-B*51:01+ individuals diagnosed before 1997, but since then RT135T has markedly declined while RT135L has increased among non-hemophiliac individuals. We demonstrated that RT135V selection by HLA-B*52:01-restricted TI8-specific T-cells led to the creation of a new HLA-C*12:02-restricted epitope TN9-8V. We further showed that TN9-8V-specific HLA-C*12:02-restricted T cells selected RT135L while TN9-8T-specific HLA-C*12:02-restricted T cells suppressed replication of the RT135T variant. Thus, population-level accumulation of the RT135L mutation over time in Japan can be explained by initial targeting of the TI8 epitope by HLA-B*52:01-restricted T-cells, followed by targeting of the resulting escape mutant by HLA-C*12:02-restricted T-cells. We further demonstrate that this phenomenon is particular to Japan, where the HLA-B*52:01-C*12:02 haplotype is common: RT135L did not accumulate over a 15-year longitudinal analysis of HIV sequences in British Columbia, Canada, where this haplotype is rare. Together, our observations reveal that T-cell responses to sequentially emerging viral escape mutants can shape long-term HIV-1 population dynamics in a host population-specific manner.

Identifiants

pubmed: 33370400
doi: 10.1371/journal.ppat.1009177
pii: PPATHOGENS-D-20-02119
pmc: PMC7833229
doi:

Substances chimiques

Epitopes, T-Lymphocyte 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009177

Subventions

Organisme : CIHR
ID : PJT-148621
Pays : Canada

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS Pathog. 2019 Aug 9;15(8):e1007970
pubmed: 31398241
PLoS One. 2009 Aug 19;4(8):e6687
pubmed: 19690614
J Virol. 2012 Dec;86(24):13202-16
pubmed: 23055555
Trends Mol Med. 2001 Sep;7(9):379-81
pubmed: 11530315
Microbiol Immunol. 1988;32(8):851-5
pubmed: 3143898
Nat Med. 2016 Jun;22(6):606-13
pubmed: 27183217
Nature. 2009 Apr 2;458(7238):641-5
pubmed: 19242411
J Virol. 2017 Jan 31;91(4):
pubmed: 27903797
J Virol. 2005 Oct;79(20):12952-60
pubmed: 16188997
PLoS Genet. 2014 Apr 24;10(4):e1004295
pubmed: 24762668
J Immunol. 2005 Jun 15;174(12):7524-30
pubmed: 15944251
J Exp Med. 2006 May 15;203(5):1357-69
pubmed: 16682496
Science. 1996 Oct 4;274(5284):94-6
pubmed: 8810254
J Virol. 2019 Mar 21;93(7):
pubmed: 30674626
PLoS Pathog. 2007 Jul;3(7):e94
pubmed: 17616974
J Immunol. 2014 Jul 1;193(1):77-84
pubmed: 24899498
Cell Rep. 2016 Jun 7;15(10):2279-2291
pubmed: 27239036
J Virol. 2005 Nov;79(21):13239-49
pubmed: 16227247
J Immunol. 2011 Jul 15;187(2):684-91
pubmed: 21670313
J Infect Dis. 2017 Dec 12;216(11):1415-1424
pubmed: 28968792
J Virol. 2015 Jul;89(14):7363-72
pubmed: 25972553
J Exp Med. 2005 Mar 21;201(6):891-902
pubmed: 15781581
Tissue Antigens. 2000 Dec;56(6):522-9
pubmed: 11169242
Nat Med. 2004 Mar;10(3):229-30
pubmed: 14991039
Virology. 2006 Jan 20;344(2):354-62
pubmed: 16219331
Eur J Immunol. 2011 Jan;41(1):97-106
pubmed: 21182081
J Virol. 2006 Oct;80(19):9519-29
pubmed: 16973556
J Exp Med. 2009 Apr 13;206(4):909-21
pubmed: 19307327
Trends Microbiol. 2015 Apr;23(4):212-24
pubmed: 25613992
J Immunol. 1982 Jun;128(6):2804-6
pubmed: 6176653
J Virol. 2013 Feb;87(4):2253-63
pubmed: 23236061
Nat Med. 2004 Mar;10(3):282-9
pubmed: 14770175
Curr Opin Immunol. 2004 Aug;16(4):470-6
pubmed: 15245741
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
J Virol. 2002 Aug;76(15):7535-43
pubmed: 12097566
J Virol. 2015 May;89(10):5330-9
pubmed: 25741000
Retrovirology. 2014 Aug 29;11:64
pubmed: 25212686
J Virol. 2008 Jul;82(13):6434-46
pubmed: 18434400
J Virol. 2012 Oct;86(19):10870-2
pubmed: 22811530
Virology. 2014 Feb;450-451:34-48
pubmed: 24503065
J Virol. 2007 Jan;81(1):193-201
pubmed: 17065207
Br J Haematol. 1987 Feb;65(2):249-50
pubmed: 3644665
EBioMedicine. 2018 Oct;36:103-112
pubmed: 30249546
Cell Rep. 2016 Nov 22;17(9):2210-2220
pubmed: 27880898
J Virol. 2010 Jul;84(14):7151-60
pubmed: 20410273
Microbiol Immunol. 2010 Apr;54(4):196-205
pubmed: 20377748
Tissue Antigens. 2015 Apr;85(4):252-9
pubmed: 25789826
Nat Med. 2004 Mar;10(3):275-81
pubmed: 14966520
J Virol. 2015 Nov 11;90(3):1244-58
pubmed: 26559841
Nat Med. 1997 Feb;3(2):212-7
pubmed: 9018241
PLoS One. 2008 Jun 18;3(6):e2422
pubmed: 18560583
PLoS One. 2013 Dec 03;8(12):e80045
pubmed: 24312453
Nature. 2001 Jul 19;412(6844):334-8
pubmed: 11460164
J Exp Med. 2001 Feb 5;193(3):375-86
pubmed: 11157057
AIDS. 2018 Sep 10;32(14):1927-1938
pubmed: 30048246
J Immunol. 2014 Nov 15;193(10):4814-22
pubmed: 25305317
J Exp Med. 2016 Sep 19;213(10):2049-63
pubmed: 27551154
Retrovirology. 2009 Aug 10;6:72
pubmed: 19664284
PLoS Pathog. 2010 Nov 18;6(11):e1001196
pubmed: 21124991
Science. 2002 May 24;296(5572):1439-43
pubmed: 12029127

Auteurs

Tomohiro Akahoshi (T)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Hiroyuki Gatanaga (H)

Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Tokyo, Japan.
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

Nozomi Kuse (N)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Tokyo, Japan.

Takayuki Chikata (T)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Tokyo, Japan.

Madoka Koyanagi (M)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Naoki Ishizuka (N)

Cancer Institute Hospital of JFCR, Tokyo, Japan.

Chanson J Brumme (CJ)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Department of Medicine, University of British Columbia, Vancouver, Canada.

Hayato Murakoshi (H)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Tokyo, Japan.

Zabrina L Brumme (ZL)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.

Shinichi Oka (S)

Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Tokyo, Japan.
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

Masafumi Takiguchi (M)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH